[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=3ff696d9853a86473425700a3f2f46773c6f7ac0d44c8d581d0f2215eeabec14",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743525840,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
      "id": 133676059,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=3ff696d9853a86473425700a3f2f46773c6f7ac0d44c8d581d0f2215eeabec14"
    }
  },
  {
    "ts": null,
    "headline": "Biotech stocks slide as Marks resignation seen being negative for sector",
    "summary": "Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit",
    "url": "https://finnhub.io/api/news?id=254d158cbf2c958ffa39dd784453958618f4931103736807bbadab76abc44dcf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743522637,
      "headline": "Biotech stocks slide as Marks resignation seen being negative for sector",
      "id": 133645467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit",
      "url": "https://finnhub.io/api/news?id=254d158cbf2c958ffa39dd784453958618f4931103736807bbadab76abc44dcf"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals",
    "summary": "Alcon, Glaukos and Regeneron Pharmaceuticals are part of the Zacks top Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=e7c2b00fc77aa546a5b183fed565f429e62d9954f121e950238a866f848b56cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743518940,
      "headline": "The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals",
      "id": 133647230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Alcon, Glaukos and Regeneron Pharmaceuticals are part of the Zacks top Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=e7c2b00fc77aa546a5b183fed565f429e62d9954f121e950238a866f848b56cb"
    }
  }
]